Clinical Trials Browser

Phase 1/2 × Ado-Trastuzumab Emtansine × Breast × Clear all

NCT06324357 2026-03-18

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 1/2 Terminated

HER2-positive Breast Cancer

NCT03190967 2023-10-11

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Phase 1/2 Terminated

12 enrolled 16 charts

Brain Neoplasms, Breast Neoplasms

NCT04298918 2021-11-08

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02658084 2019-04-17

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Phase 1/2 Terminated

2 enrolled 7 charts

Breast Neoplasms

NCT00934856 2017-04-06

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Phase 1/2 Completed

98 enrolled 40 charts

Breast Neoplasms

NCT00951665 2016-06-24

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

107 enrolled 31 charts

Breast Neoplasms

NCT00875979 2013-12-24

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Phase 1/2 Completed

67 enrolled 9 charts

Breast Neoplasms